UpToDate Contents

全文を閲覧するには購読必要です。 To read the full text you will need to subscribe.

English Journal

Metronomic oral combination chemotherapy with capecitabine and cyclophosphamide: a phase II study in patients with HER2-negative metastatic breast cancer.

Yoshimoto M, Takao S, Hirata M, Okamoto Y, Yamashita S, Kawaguchi Y, Takami M, Furusawa H, Morita S, Abe C, Sakamoto J.SourceBreast Center, Mita Hospital, International University of Health and Welfare, 1-4-3 Mita, Minato-ku, Tokyo, 108-8329, Japan, yoshimoto@yoshimoto-bc.com.
Cancer chemotherapy and pharmacology.Cancer Chemother Pharmacol.2012 Apr 11. [Epub ahead of print]
PURPOSE: Metronomic combination chemotherapy with the oral fluoropyrimidine doxifluridine/5'-deoxy-5-fluorouridine (5 -DFUR) and oral cyclophosphamide (C) showed promising efficacy in a single-arm study. The oral fluoropyrimidine capecitabine was designed to deliver 5-fluorouracil preferentially to
PMID 22526409

Reliability of tumor primary cultures as a model for drug response prediction: expression profiles comparison of tissues versus primary cultures from colorectal cancer patients.

Bellot GL, Tan WH, Tay LL, Koh D, Wang X.SourceCancer Science Institute of Singapore, National University of Singapore, 28 Medical Drive #02-07, Singapore 117456, Singapore. phsglb@nus.edu.sg
Journal of cancer research and clinical oncology.J Cancer Res Clin Oncol.2012 Mar;138(3):463-82. Epub 2011 Dec 21.
PURPOSE: Since primary tumor cells from patients have been used as a model for assessment of drug response for individual patients, this study aims to evaluate the reliability of such a model in colorectal cancer (CRC) in predicting the response of tumor tissues through comparison of their expressio
PMID 22186935

戸谷裕之,竹吉泉,須納瀬豊,吉成大介,戸塚統,小川博臣,平井圭太郎,高橋憲史,田中和美,平戸純子
北関東医学 61(2), 187-191, 2011
… 術後は外来でPaclitaxel (PTX)＋Doxifluridine (5-DFUR) (PTX : 80mg/m2＋5-DFUR : 533mg/m2) による化学療法を施行し, 9か月間は再発徴候がなかった. …
NAID 130000872631

Phase I study of irinotecan and doxifluridine for metastatic colorectal cancer focusing on the UGT1A1^*28 polymorphism

HAZAMA Shoichi,NAGASHIMA Atsushi,KONDO Hiroshi,YOSHIDA Shin,SHIMIZU Ryoichi,ARAKI Atsuhiro,YOSHINO Shigefumi,OKAYAMA Naoko,HINODA Yuji,OKA Masaaki
Cancer science 101(3), 722-727, 2010-03-10
NAID 10026589707